AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02146495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial
Description: Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology
Study NCT02146495 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial
Description: Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.
Study NCT01947413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
Study NCT01947413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
Study NCT02613000 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01947413 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham theta burst stimulation
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
Study NCT03181113 — intervention group
Intervention type: DRUG
Intervention: Peginterferon Alfa-2A
Description: pre-received standard peginterferon alfa-2a therapy
Study NCT01975688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD.
Study NCT02998957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuTENS
Description: Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
Study NCT02998957 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AcuTENS
Description: Portable TENS electrostimulation device with no electrical output
Study NCT03670030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
Study NCT01285349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple HIV/STI prevention intervention
Study NCT01285349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI prevention
Study NCT01285349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual HIV/STI prevention
Study NCT01285349 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Couple Wellness Promotion
Study NCT02678429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change DBS programming
Description: Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
Study NCT02678429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Change DBS programming
Description: Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
Study NCT00545870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal application
Study NCT00545870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal application
Study NCT03225859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Program
Description: This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
Study NCT01685398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate eye drop
Study NCT01685398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01671579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bowel ultrasound
Description: The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
Study NCT01671579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance enterography (MRE)
Description: The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
Study NCT03310060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tisseel
Description: Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
Study NCT03310060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
Study NCT03310060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
Study NCT00049387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO
Study NCT00049387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT00049387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo partial brain radiation therapy
Study NCT00038389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vioxx
Description: Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
Study NCT01794338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice Arm
Description: Biologic mesh to be placed during hernia repair surgery
Study NCT01794338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-A Arm
Description: Bioabsorbable mesh to be placed during hernia repair surgery
Study NCT00336856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
Study NCT00336856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
Study NCT03140059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement will be performed to decontaminate root surface
Study NCT03140059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated application of aPDT
Description: Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
Study NCT02043899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [124I]meta-Iodobenzylguanidine
Description: Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
Study NCT03940768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Description: Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
Study NCT03940768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus plantarum 299v
Description: Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
Study NCT03940768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administration of placebo in cancer patients who receive home enteral nutrition.
Study NCT03940768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo in cancer patients who receive home enteral nutrition.
Study NCT03817047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical education
Description: Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary.
Study NCT03817047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical active learning
Description: The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
Study NCT03817047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus.
Study NCT03817047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be happy
Description: The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
Study NCT02522624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Description: Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
Study NCT00749710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: ORIF - surgical treatment
Study NCT00749710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no antiaggregant therapy
Description: ORIF - surgical treatment
Study NCT03196609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of stool and serum samples
Description: During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)
Study NCT00458224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental counseling
Description: Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
Study NCT00854100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + placebo
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study NCT00798759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
Study NCT00798759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
Study NCT04273880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 10mg of MPH taken an hour and a half before one of the testing sessions.
Study NCT04273880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: 90 mg of Vitamin C taken an hour and a half before the other testing session
Study NCT00947440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-072
Description: See arm description for more information
Study NCT03320824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Dermal Filler
Description: hyaluronic acid
Study NCT03320824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: FDA Approved Dermal Filler
Description: hyaluronic acid
Study NCT03970044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 MG
Description: Glucagon-like peptide-1 receptor
Study NCT03970044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 MG
Description: Glucagon-like peptide-1 receptor
Study NCT03970044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG
Description: sodium-glucose co-transporter 2 (SGLT2) inhibitor
Study NCT02292212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViE-21
Description: The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
Study NCT00074958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1 mg/kg every 2 weeks
Study NCT00854100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + cariprazine (0.1-0.3 mg/day)
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study NCT04582838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse oximeter
Description: In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis.
Study NCT00854100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + cariprazine (1-2 mg/d)
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study NCT03607032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respin Pad
Description: RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
Study NCT04582838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG signal is used to monitor respiratory rate (RR).
Study NCT03970044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: sodium-glucose co-transporter 2 (SGLT2) inhibitor
Study NCT04503187 — intervention group
Intervention type: BEHAVIORAL
Intervention: Visuomotor leg reaching task
Description: Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
Study NCT01901796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
Study NCT02270996 — intervention group
Intervention type: OTHER
Intervention: Antimicrobial Stewardship Program
Description: Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
Study NCT03470181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Ensure
Description: Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
Study NCT02575209 — intervention group
Intervention type: OTHER
Intervention: GENDER
Study NCT00407381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
Study NCT03607032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment
Description: medical aerosol session followed by aspiration or not, as required
Study NCT03607032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Description: medical aerosol session followed by aspiration or not, as required
Study NCT00407381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser photocoagulation in either focal or grid pattern as determined by investigator.
Study NCT01959165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 low dose
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
Study NCT01959165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 medium dose
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
Study NCT01959165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 high dose
Description: MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
Study NCT01959165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered by SC on Day 1, Week 2,4, and 8
Study NCT02381379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon-α-2a
Description: Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
Study NCT01709331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
Study NCT01709331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)